LBA-001Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH). (24th June 2018) - Zhu, A; Finn, R; Galle, P; Llovet, J; Blanc, J F; Okusaka, T; Chau, I; Abada, P; Hsu, Y; Kudo, M